drugset / Trial / NCT03505502

Reducing Blood Loss During Cesarean Myomectomy With Tranexamic Acid

NCT03505502 ↗

Completed 120 enrolled Aswan University Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study was a double-blinded randomized controlled study conducted at Aswan University, Egypt from January 2018 to January 2020. Study inclusion criteria were women who attended the outpatient obstetric clinic, seeking antenatal care diagnosed with leiomyomas with pregnancy and with myoma staging from (3 to 6) according to FIGO staging. scheduled to undergo cesarean myomectomy (11) Exclusion criteria were: 1-Patients undergone vaginal delivery.2-Patients with a history of thromboembolic disease. 3-Cervical and broad ligament myoma. 4-Myoma FIGO staging

Timeline

Start
2018-01-01
Primary completion
2020-01-01
Completion
2020-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 1 g Intravenous
Subject Tranexamic Acid Small molecule 2 g Intravenous

Indications

No indication recorded.